Skip to main content
    S

    Salarius Pharmaceuticals Inc (SLRX)

    Official site

    BIOTECHNOLOGY

    $0.84
    +0.19 (+29.23%)

    Last updated: Jan 07, 2026 at 4:00 PM ET

    Salarius Pharmaceuticals Inc (SLRX) Financials: Revenue, Profit and Cash Flow

    Updated Nov 14, 2025. Financial statements from company filings, amounts in US dollars.

    Salarius Pharmaceuticals reported revenue of $0 for the fiscal year ended Dec 31, 2024. That year, net income was -$5.58M, operating cash flow was -$4.53M and free cash flow was -$4.53M. The quarter ended Sep 30, 2025 had revenue of $0 and net income of -$873.47K.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2024, with an operating loss of $5.73M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0-100.0%N/AN/AN/A
    Dec 2021$1.84M-64.8%99.0%-696.3%-693.8%
    Dec 2020$5.23M+51.0%100.0%-148.8%-140.5%
    Dec 2019$3.47M+313.5%100.0%-238.5%-200.2%
    Dec 2018$838.00K-34.3%48.6%-2634.1%-2616.0%
    Dec 2017$1.27M+26.1%60.2%-2723.6%-2700.7%
    Dec 2016$1.01MN/A34.4%-3945.2%-3906.3%
    Dec 2015N/AN/AN/AN/AN/A
    Annual, fiscal years ended Dec 2015 to Dec 2024

    Income Statement

    In the fiscal year ended Dec 2024, the net loss narrowed from the year before. In the quarter ended Sep 2025, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015
    Revenue$0$0$0$1.84M$5.23M$3.47M$838.00K$1.27M$1.01MN/A
    Cost of revenue$4.42K$10.05K$6.68K$19.18K$6.91K$4.02K$431.00K$507.00K$663.00K$49.88K
    Gross profit-$4.42K-$10.05K-$6.68K$1.82M$5.23M$3.47M$407.00K$768.00K$348.00K-$49.88K
    Research and development$770.03K$7.17M$15.84M$8.55M$6.91M$4.02M$11.91M$16.99M$20.38M$12.75M
    Operating income-$5.73M-$12.89M-$31.84M-$12.81M-$7.79M-$8.27M-$22.07M-$34.73M-$39.89M-$29.21M
    Net income-$5.58M-$12.54M-$31.61M-$12.77M-$7.35M-$6.94M-$21.92M-$34.43M-$39.49M-$29.14M
    EBITDA-$5.73M-$12.88M-$22.97M-$12.79M-$7.59M-$8.14M-$21.85M-$34.40M-$39.61M-$29.16M
    Fiscal years ended Dec 2015 to Dec 2024

    Quarterly

    Line itemSep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Revenue$0$0$0$4.43K$0$0$0$17.89K$0$0$0$0
    Gross profit-$1.11K-$1.11K-$1.11K$2.21K-$1.10K-$1.11K-$1.11K$16.79K-$5.61K-$1.67K-$1.67K-$1.67K
    Operating income-$895.13K-$965.57K-$1.72M-$1.49M-$1.01M-$1.47M-$1.77M-$970.70K-$2.53M-$3.97M-$5.42M-$6.48M
    Net income-$873.47K-$957.83K-$1.71M-$1.46M-$972.12K-$1.42M-$1.72M-$881.80K-$2.44M-$3.88M-$5.34M-$6.37M
    Last 12 quarters

    Balance Sheet

    As of Dec 2024, cash and equivalents exceeded short-term debt of $221.87K by $2.21M.

    Annual

    Line itemDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015
    Total assets$3.02M$6.59M$14.65M$40.83M$24.93M$13.89M$10.39M$34.99M$63.21M$95.07M
    Current assets$2.99M$6.52M$14.52M$30.16M$15.80M$4.69M$10.32M$34.54M$62.47M$92.25M
    Cash and equivalents$2.43M$5.90M$12.11M$29.21M$11.12M$3.74M$9.83M$19.19M$22.42M$66.69M
    Total liabilities$1.51M$1.30M$4.27M$2.11M$2.77M$3.31M$1.11M$5.89M$3.90M$2.88M
    Short-term debt$221.87K$289.64KN/AN/A$477.03K$502.33KN/AN/AN/AN/A
    Shareholder equity$1.51M$5.29M$10.38M$38.72M$22.16M$10.58M$9.28M$29.11M$59.32M$92.19M
    Fiscal years ended Dec 2015 to Dec 2024

    Quarterly

    Line itemSep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Total assets$6.10M$1.39M$2.34M$3.02M$3.86M$3.55M$4.88M$6.59M$8.40M$12.06M$10.06M$14.65M
    Total liabilities$1.85M$2.22M$2.28M$1.51M$934.58K$1.18M$1.23M$1.30M$2.32M$3.64M$4.50M$4.27M
    Cash and equivalents$4.81M$794.89K$1.80M$2.43M$3.28M$3.27M$4.37M$5.90M$7.58M$11.54M$9.27M$12.11M
    Shareholder equity$4.25M-$829.72K$61.87K$1.51M$2.92M$2.38M$3.65M$5.29M$6.08M$8.41M$5.56M$10.38M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2024.

    Annual

    Line itemDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015
    Operating cash flow-$4.53M-$12.85M-$17.60M-$10.20M-$10.31M-$11.58M-$23.60M-$27.72M-$32.05M-$20.75M
    Capital expenditures$0$3$1.50M$3$2.60K$2.60K$2.60K$113.50K$559.38K$265.62K
    Free cash flow-$4.53M-$12.85M-$19.10M-$10.20M-$10.31M-$11.58M-$23.60M-$27.84M-$32.61M-$21.01M
    Dividends paidN/AN/AN/AN/A$0$133.59K$133.59K$133.59K$133.59KN/A
    Investing cash flowN/AN/A-$1.50M-$1.50M-$2.60K$5.61M$14.12M$24.49M-$12.24M-$27.27M
    Financing cash flow$1.06M$6.64M$1.99M$28.30M$17.69M$3.58M$118.01K$2.63K$22.10K$80.84M
    Fiscal years ended Dec 2015 to Dec 2024

    Quarterly

    Line itemSep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Operating cash flow-$1.65M-$862.30K-$1.18M-$742.52K-$1.36M-$1.07M-$1.35M-$1.51M-$3.75M-$4.42M-$3.17M-$4.71M
    Capital expenditures$0$4$4$0$2$2$5$0$4$0$0$1.50M
    Free cash flow-$1.65M-$862.30K-$1.18M-$742.52K-$1.36M-$1.07M-$1.35M-$1.51M-$3.75M-$4.42M-$3.17M-$6.21M
    Last 12 quarters

    Frequently Asked Questions About SLRX

    What is Salarius Pharmaceuticals' annual revenue?

    Salarius Pharmaceuticals reported revenue of $0 for the fiscal year ended Dec 31, 2024.

    Is Salarius Pharmaceuticals profitable?

    No. Salarius Pharmaceuticals reported net income of -$5.58M for the fiscal year ended Dec 31, 2024.

    How much free cash flow does SLRX generate?

    For the fiscal year ended Dec 31, 2024, operating cash flow of -$4.53M minus capital expenditures of $0 produced free cash flow of -$4.53M.

    How much debt does Salarius Pharmaceuticals have?

    The balance sheet dated Dec 31, 2024 reported short-term debt of $221.87K and cash and equivalents of $2.43M.